Knee InjuriesNCT06078072
Biomaterials and Mesenchymal Stem/Stromal Cells in the Treatment of Knee Articular Surface Lesions
An observational study of Knee Injuries and Cartilage Injury, run by University Medical Centre Ljubljana at 1 site in Slovenia.
Trial summary
The goal of this observational study is to evaluate the combined single-step approach with biomaterials and mesenchymal stem/stromal cells in the treatment of knee articular surface lesions. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Knee Injuries, Cartilage Injury, Osteochondral Defect
- What is being tested?
- Biomaterials augmented with mesenchymal stem/stromal cells
- Type of treatment
- Surgery or procedure
- How many people
- 90 participants
- Where
- 1 siteSlovenia
- Study dates
- 1 Sep 2022to 31 Oct 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Adult, Older adult
Study population: 100-150 adult patients (age:18-65) with knee articular surface lesions (size ≥ 1.5 cm2, ICRS grades 3-4) surgically treated with the combined single-step approach (scaffold and fBMA) between January 2013 and December 2020.
Who may be able to join
- informed consent
- patients treated with combined single-step procedure (scaffold and fBMA) for knee articular surface lesions, between January 2013 and December 2020
- symptomatic knee articular surface lesions (International cartilage repair society (ICRS) grades 3-4, size ≥ 1.5 cm2) unresponsive to conservative treatment,
- only mild concomitant osteoarthritis (Kellgren-Lawrence grades 1-2)
Who cannot join
- patients that refuse to participate in the study
- non responders to the invitation to answer PROMs at the follow-up
- associated medical conditions (inflammatory, metabolic, neoplastic, etc.) that could directly handicap the musculoskeletal system or indirectly impact the quality of life
Trial locations and contacts
1 site in 1 country.
About this study
The goal of this observational study is to evaluate the combined single-step approach with biomaterials and mesenchymal stem/stromal cells in the treatment of knee articular surface lesions. The clinical analysis of the treatment outcomes, regarding postoperative improvements and safety, is going to be accompanied with laboratory analysis of the intraoperatively applied cellular products.
The main hypothesis are: (1) such combined single-step procedure significantly improves patients' functioning and quality of life; (2) this therapeutic approach is safe; (3) cellular parameters of the applied filtered bone marrow aspirate (fBMA) impact treatment outcomes, among other potential predictors.
Researchers will compare subjective (questionnaire) and objective (clinical examination) status of patients before and after the operation, record any potential complications and perform regression analysis to assess the influence of potential predictors on postoperative improvements.
- Conditions
- Knee Injuries, Cartilage Injury, Osteochondral Defect
- Being tested
- Biomaterials augmented with mesenchymal stem/stromal cells
- Keywords
- Biomaterials, Mesenchymal stem/stromal cells, Bone marrow aspirate, Cartilage, Osteochondral lesion, Knee
- Medical subject headings
- Knee Injuries
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Biomaterials augmented with mesenchymal stem/stromal cellsProcedure or surgery
Combined single-step procedure of treating knee articular surface lesions with biomaterials (scaffolds) and mesenchymal stem cells (filtered bone marrow aspirate concentrate)
What is being measured
The primary outcome is the main question the study is designed to answer.
Knee injury and Osteoarthritis Outcome Score (KOOS) subscale Pain postoperative improvement
Knee injury and Osteoarthritis Outcome Score (KOOS) assesses patients' pain (9 items), other symptoms (7 items), function in daily living (17 items), function in sport and recreation (5 items), and knee related quality of life (4 items). Scores range from 0 to 100 with a score 0 being the worst score and 100 indicating no impairment.
KOOS subscale Pain postoperative improvement will be calculated as difference between preoperative and postoperative scores at the final follow up.
Paired Student t test will be applied to compare preoperative and postoperative values of KOOS subscale Pain.
Measured: At least 24 months after the operation
Secondary outcomes (7)
Knee injury and Osteoarthritis Outcome Score (KOOS) subscales postoperative improvements
Originally published in 1998, the Knee injury and Osteoarthritis Outcome Score (KOOS) assesses patient pain (9 items), other symptoms (7 items), function in daily living (17 items), function in sport and recreation (5 items), and knee related quality of life (4 items). Scores range from 0 to 100 with a score 0 being the worst score and 100 indicating no impairment.
KOOS subscales postoperative improvements will be calculated as differences between preoperative and postoperative scores at the final follow up. As secondary outcome measures will be calculated all KOOS subscales improvements, beside KOOS subscale Pain, which is determined as the primary outcome measure.
Paired Student t test will be applied to compare preoperative and postoperative values of all KOOS subscales.
Measured: At least 24 months after the operation
Complications (SAE and GF)
Serious adverse events (SAE) are defined as any hospitalization or revision surgery (arthrofibrosis, synovitis, infection, hardware problem, pulmonary embolism, etc.), while graft failures (GF) as revision surgery to the lesion or confirmed indication for it. SAE will be further classified as related (arthrofibrosis, synovitis, graft hypertrophy/delamination, etc.) or unrelated (hardware removal, meniscus or ligament injuries, new cartilage lesions, pulmonary embolism, etc.) to the graft.
Measured: Recording until the final follow up (minimum 24 months after the operation)
Cellular parameters of intraoperatively applied filtered Bone Marrow Aspirate (fBMA)
Samples for cell counting (100 µl), fibroblast colony forming units (CFU-F) assay (1-2 ml) and flow cytometry (1-2 ml) will be taken before and after BMA processing with filter-based separation device. The total nucleated cell (TNC) count will be determined by counting white blood cells with hematology analyzer COULTER® Ac·T diff2™ (Beckman Coulter, Fullerton, CA, USA). MSCs content will be estimated with flow cytometry (FACSCalibur, BD Biosciences, San Jose, CA, USA) by determining CD271+ and CD45-cells, and concomitant assessment of their viability using 7-amino-actinomycin D (7-AAD) dye. Also, the CFU-F assay, which is a functional assay for measuring the frequency of MSCs with the colony forming abilities, will be performed. Briefly, cells will be seeded at least in duplicates into well culture plates and cultured in standard conditions: 37 °C, 5% CO2. After 14 days, colonies containing ≥ 50 fibroblastic cells will be manually counted under the stereomicroscope.
Measured: Finsihed in 14 days after the procedure
Tegner Activity Scale (TAS) postoperative improvement
Tegner Activity Scale (TAS) is a one-item score that graded activity based on work and sports activities on a 11-level scale from 0 to 10. Zero represents disability because of the knee problems and 10 represents national or international level soccer.
TAS postoperative improvement will be calculated as difference between preoperative and postoperative scores at the final follow up.
Paired Student t test will be applied to compare preoperative and postoperative values of TAS.
Measured: At least 24 months after the operation
European Quality of Life 5 Dimensions 3 Level (EQ-5D-3L) postoperative improvement
EQ-5D-3L descriptive system consists of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression . Each dimension has 3 levels: no problems, some problems, and extreme problems. The respondent is asked to indicate his or her health state by ticking the box that marks the most appropriate level of problems in each dimension. A unique health state can be described according to the responses to the 5 questions. Health states defined in this way may be converted into a single summary index by applying a formula that attaches values to each of the levels in each dimension. States can be converted to a single value where 1 is equivalent to full health and 0 to a state equivalent to death.
EQ-5D-3L postoperative improvement will be calculated as difference between preoperative and postoperative scores at the final follow up.
Paired Student t test will be applied to compare preoperative and postoperative values of EQ-5D-3L .
Measured: At least 24 months after the operation
EuroQol Visual Analogue Scale (EQ-VAS) postoperative improvement
EQ-VAS records the patient's self-rated health on a vertical visual analogue scale from 0 to 100, where 0 represents the worst health state imaginable and 100 represents the best health state imaginable.
EQ-VAS postoperative improvement will be calculated as difference between preoperative and postoperative scores at the final follow up.
Paired Student t test will be applied to compare preoperative and postoperative values of EQ-VAS5.
Measured: At least 24 months after the operation
Potential predictors (patients' demographics, medical history, joint and lesions' characteristics, surgical and cellular parameters) of the clinical outcomes (KOOS subscales, EQ-5D-3L, EQ-VAS, TAS)
Regression models will be used to assess the influence of proposed predictors (patients' demographics, medical history, joint and lesions' characteristics, surgical and cellular parameters) on the postoperative improvements in clinical outcome measures (KOOS subscales, EQ-5D-3L, EQ-VAS, TAS). Statistical analysis will be performed with SPSS (version 25.0; IBM, Chicago, IL, USA).
Measured: At the time of statistical analysis
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Oct 2023
- Study start1 Sep 2022
- Primary completion31 Aug 2023
- Study completion31 Oct 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Knee InjuriesStudies of the same condition, open and under way.
- More trials run by University Medical Centre LjubljanaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 90 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Medical Centre Ljubljana
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Matic Kolar, MD, Principal investigator, University Medical Centre Ljubljana
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06078072
- Sponsor's protocol ID
- University Medical Centre
- Status last verified
- Oct 2023
- First submitted
- 2 Aug 2023
- Last updated
- 30 Nov 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Kolar M, Veber M, Girandon L, Drobnic M. A Biomimetic Osteochondral Scaffold Augmented With Filtered Bone Marrow Aspirate for the Treatment of Joint Surface Lesions in the Knee. Am J Sports Med. 2024 Jun;52(7):1826-1833. doi: 10.1177/03635465241247788. Epub 2024 May 20.
PubMed 38767159
Study at a glance
From the registry record, last updated by the sponsor on 30 Nov 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Biomaterials and Mesenchymal Stem/Stromal Cells in the Treatment of Knee Articular Surface Lesions
- ClinicalTrials.gov ID
- NCT06078072
- Acronym / sponsor ID
- University Medical Centre
- Conditions
- Knee Injuries, Cartilage Injury, Osteochondral Defect
- Keywords
- Biomaterials, Mesenchymal stem/stromal cells, Bone marrow aspirate, Cartilage, Osteochondral lesion, Knee
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 90 participants (actual)
- Lead sponsor
- University Medical Centre LjubljanaUniversity, hospital or other
- Study start
- 1 Sep 2022 (actual)
- Primary completion
- 31 Aug 2023 (actual)
- Study completion
- 31 Oct 2023 (actual)
- First posted
- 11 Oct 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to evaluate the combined single-step approach with biomaterials and mesenchymal stem/stromal cells in the treatment of knee articular surface lesions. The clinical analysis of the treatment outcomes, regarding postoperative improvements and safety, is going to be accompanied with laboratory analysis of the intraoperatively applied cellular products.
The main hypothesis are: (1) such combined single-step procedure significantly improves patients' functioning and quality of life; (2) this therapeutic approach is safe; (3) cellular parameters of the applied filtered bone marrow aspirate (fBMA) impact treatment outcomes, among other potential predictors.
Researchers will compare subjective (questionnaire) and objective (clinical examination) status of patients before and after the operation, record any potential complications and perform regression analysis to assess the influence of potential predictors on postoperative improvements.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- 100-150 adult patients (age:18-65) with knee articular surface lesions (size ≥ 1.5 cm2, ICRS grades 3-4) surgically treated with the combined single-step approach (scaffold and fBMA) between January 2013 and December 2020.
Key inclusion criteria (4 listed)
- informed consent
- patients treated with combined single-step procedure (scaffold and fBMA) for knee articular surface lesions, between January 2013 and December 2020
- symptomatic knee articular surface lesions (International cartilage repair society (ICRS) grades 3-4, size ≥ 1.5 cm2) unresponsive to conservative treatment,
- only mild concomitant osteoarthritis (Kellgren-Lawrence grades 1-2)
Key exclusion criteria (3 listed)
- patients that refuse to participate in the study
- non responders to the invitation to answer PROMs at the follow-up
- associated medical conditions (inflammatory, metabolic, neoplastic, etc.) that could directly handicap the musculoskeletal system or indirectly impact the quality of life
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Biomaterials augmented with mesenchymal stem/stromal cellsCombined single-step procedure of treating knee articular surface lesions with biomaterials (scaffolds) and mesenchymal stem cells (filtered bone marrow aspirate concentrate) | Procedure or surgery | – |
Primary outcome
Knee injury and Osteoarthritis Outcome Score (KOOS) subscale Pain postoperative improvement
Time frame: At least 24 months after the operation
Knee injury and Osteoarthritis Outcome Score (KOOS) assesses patients' pain (9 items), other symptoms (7 items), function in daily living (17 items), function in sport and recreation (5 items), and knee related quality of life (4 items). Scores range from 0 to 100 with a score 0 being the worst score and 100 indicating no impairment. KOOS subscale Pain postoperative improvement will be calculated as difference between preoperative and postoperative scores at the final follow up. Paired Student t test will be applied to compare preoperative and postoperative values of KOOS subscale Pain.
7 secondary outcomes
Knee injury and Osteoarthritis Outcome Score (KOOS) subscales postoperative improvements
Time frame: At least 24 months after the operation
Complications (SAE and GF)
Time frame: Recording until the final follow up (minimum 24 months after the operation)
Cellular parameters of intraoperatively applied filtered Bone Marrow Aspirate (fBMA)
Time frame: Finsihed in 14 days after the procedure
Tegner Activity Scale (TAS) postoperative improvement
Time frame: At least 24 months after the operation
European Quality of Life 5 Dimensions 3 Level (EQ-5D-3L) postoperative improvement
Time frame: At least 24 months after the operation
EuroQol Visual Analogue Scale (EQ-VAS) postoperative improvement
Time frame: At least 24 months after the operation
Potential predictors (patients' demographics, medical history, joint and lesions' characteristics, surgical and cellular parameters) of the clinical outcomes (KOOS subscales, EQ-5D-3L, EQ-VAS, TAS)
Time frame: At the time of statistical analysis
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Nov 2023.
- Derived from this study: PubMed 38767159Kolar M, Veber M, Girandon L, Drobnic M. A Biomimetic Osteochondral Scaffold Augmented With Filtered Bone Marrow Aspirate for the Treatment of Joint Surface Lesions in the Knee. Am J Sports Med. 2024 Jun;52(7):1826-1833. doi: 10.1177/03635465241247788. Epub 2024 May 20.
Related trials for Knee Injuries
Not yet recruiting
Stair Biomechanics and Vibration Study After ACLR
Anterior Cruciate Ligament Reconstruction (ACLR), Anterior Cruciate Ligament Injury
RecruitingObservational study
Exploring Factors Linked to Worsening Over Time in People With Early-stage Knee Osteoarthritis and Those With Prior Proven Acute Knee Injury.
Knee Osteoarthritis
Not yet recruiting
Supporting Athletes' Return to Sports After ACL Reconstruction: A Study of a Psychological Readiness Program
Anterior Cruciate Ligament Reconstruction, Anterior Cruciate Ligament Injuries
Recruiting
Effects of Pulsed Electromagnetic Field Therapy on Meniscal Healing, Symptom Relief, and Knee Function
Meniscal Tears
Not yet recruiting
Negative Pressure Wound Therapy Devices in Total Knee Arthroplasty
Wound Surgical, Diabetes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Matic Kolar, MD principal investigator
University Medical Centre Ljubljana
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Knee Injuries and Cartilage Injury, run by University Medical Centre Ljubljana at 1 site in Slovenia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Slovenia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Knee injury and Osteoarthritis Outcome Score (KOOS) subscale Pain postoperative improvement (time frame: At least 24 months after the operation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06078072, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Nov 2023.